Heidi Hagen

Heidi Hagen is an experienced board member and consultant in the biotechnology and pharmaceutical industries, currently serving on the boards of Applied StemCell, A-Alpha Bio, Obsidian Therapeutics, and Vericel Corporation, where Heidi also chairs the Governance Committee. Previously, Heidi held the position of Chief Technical Officer at Sonoma Biotherapeutics and Interim CEO at Ziopharm Oncology, as well as board roles with Lykan Bioscience and Vineti. Heidi's expertise includes advancing gene editing, stem cell technology, and immuno-oncology therapeutic development, supported by a solid educational background with an MBA from the UW Foster School of Business and advanced degrees in Bioengineering and Cellular and Molecular Biology from the University of Washington.